PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.

Slides:

Advertisements

Similar presentations

Advertisements

Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics Memorial.

Advances and Emerging Therapy for Lung Cancer

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.

1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee September 17, 1999.

Memorial Sloan-Kettering Cancer Center

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Abstract Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer A. Cercek, K.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Cancer Center Trials at St. Barnabas Medical Center.

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.

ACRIN 6657/CALGB Consent for Research Study Contrast-Enhanced Breast MRI and MRS: A Correlative Science Studies to Characterize Tumor Response in.

Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.

Pharmacogenomics: Studies in Breast Cancer Lynn C. Hartmann MD Mayo Clinic Cancer Center.

Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.

Howard M. Sandler, MD University of Michigan Medical School

Is Radiation Consistently Necessary for Mid-High Rectal Cancers? Assigned Viewpoint: No Great Debates Symposium New York City, NY Deb Schrag MD Dana Farber.

Treatment options depend on the following: – The stage of the cancer – Whether the cancer has recurred – The patient’s general health.

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Amy P. Abernethy, MD Task 6: Usability.

Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment.

The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena

LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.

Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)

Dr Purvish M Parikh MD, DNB, FICP, PhD, ECMO, CPI, MBA 12 th July 2014, Kolkata 17th ICRO PG Teaching Course.

MAX: International multi-centre randomised phase II/III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for.

0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,

Management of Recurrent and Advanced Tumours: When are Tumours Resectable, and Multidisciplinary Management Dr. Andrew McFadden Surgical Oncology.

Bringing the Patient Voice into Cancer Care and Research Ethan Basch, MD, MSc November 19, 2015.

Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.

Sandra A. Mitchell, PhD, CRNP Outcomes Research Branch, DCCPS

Synchronous Metastasis on Staging/Surveillance CT chest abdomen & Pelvis + CEA + MRI Liver /PET-CT Synchronous Metastasis on Staging/Surveillance CT chest.

A POST-MARKETING EVALUATION OF SAFETY CAMPTOSAR + 5-FU/LV FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER A POST-MARKETING EVALUATION OF SAFETY.

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.

Renal cell carcinoma R4 신재령 Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Copyright © 2011 Research To Practice. All rights reserved. Faculty National GI Tumor Board Clinical Investigators Provide Their Perspectives on Current.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,

¿Qué ver en ASCO 2017?.

SMDT SMDT SMDT Synchronous Metastasis on Staging/Surveillance

CCO Independent Conference Highlights

Schema of the NSABP B-34 trial evaluating adjuvant oral clodronate in patients with resected stage I and II operable breast cancer (Chemo, adjuvant chemotherapy;

The future of our patients already treated with first line chemotherapy First of all, I would like to take this opportunity to thank the Mediterranean.

Colorectal Cancer Update Patient Perspectives on Colorectal Cancer

Adjuvant chemotherapy in NSCLC

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

ICAS: CTOS 2005 Review of Studies

تهیه کننده: استاد مربوطه: بهار 1392

Colon Cancer Stages I-III

Locally Advanced NSCLC Implementing Innovation

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Joachim Pfannschmidt, MD, Hans Hoffmann, MD, Hendrick Dienemann, MD

Research Center Overview

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

Neoadjuvant Adjuvant Curative Palliative

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.

Early Diagnosis and Management of SSc-ILD

Presentation transcript:

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering Cancer Center POTENTIAL EARLY COLLABORATIONS May 24, 2010 National Cancer Institute

Industry/Commercial 1.Astra-Zeneca 2.Merck 3.Genentec 4.McKesson 5.NavigatingCancer.com

Cooperative Group Trials 1.CALGB : Memantine as neuroprotector for PCI in SCLC (Ahles) 2.NCCTG 0949/CALGB 81002: FOLFOX/Bev vs. Fluoropyrimidine/Bev in metastatic colorectal cancer in older patients (Jackson, Grothey) 3.CALGB 80903: Ph3 chemo +/- liver cytoreduction in liver metastasis-dominant colorectal cancer (Solomon/Zafar) 4.CALGB 80702: Ph3 adjuvant FOLFOX + celecoxib or placebo in resected stage III colon cancer (Meyerhardt/Shields) 5.SWOG XXX: Diarrhea evaluation (Monipoor) 6.CALGB 81001: Ph2 neoadjuvant FOLFOX +/- RT in good-risk rectal cancer (Schrag) 7.RTOG 1016: Favorable risk H/N cancer (Trotti/Ringash)

Academic 1.DFCI: Lung cancer symptoms (Cooley R01) 2.University of Tokyo: Japanese translation (Kuroda/Yamaguchi) 3.MSKCC: Oropharynx cancer longitudinal QOL (Baxi/Pfister) 4.Johns Hopkins: Patient preferences in lung cancer (Bridges)